Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) (NATELLA)

This study has been completed.
Sponsor:
Collaborators:
The Methodist Hospital System
Texas Children's Hospital
Center for Cell and Gene Therapy, Baylor College of Medicine
Information provided by (Responsible Party):
Stephen Gottschalk, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00516087
First received: August 10, 2007
Last updated: September 19, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2013
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)